Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dexmedetomidine hydrochloride (Precedex) is an imidazole derivative that is an agonist of the adrenergic alpha-2 receptor. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 35.00 | |
10 mg | In stock | $ 50.00 | |
25 mg | In stock | $ 90.00 | |
50 mg | In stock | $ 162.00 | |
100 mg | In stock | $ 238.00 | |
200 mg | In stock | $ 358.00 | |
500 mg | In stock | $ 593.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 46.00 |
Description | Dexmedetomidine hydrochloride (Precedex) is an imidazole derivative that is an agonist of the adrenergic alpha-2 receptor. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound. |
Targets&IC50 | α2-adrenoceptor:1.08 nM (IC50) |
In vivo | Conivaptan (0.03, 0.1 and 0.3 mg/kg i.v.) dose-dependently increases urine volume and reduces urine osmolality in both myocardial infarction and sham-operated rats. Conivaptan (0.3 mg/kg i.v.) significantly reduces right ventricular systolic pressure, left ventricular end-diastolic pressure, lung/body weight and right atrial pressure in myocardial infarction rats. Conivaptan (0.3 mg/kg i.v.) significantly increases dP/dt(max)/left ventricular pressure in myocardial infarction rats. [1] Conivaptan produces an acute increase in urine volume (UV), a reduction in osmolality (UOsm) and, at the end of the investigation, cirrhotic rats receiving the V(1a)/V(2)-AVP receptor antagonist does not show hyponatremia or hypoosmolality. Conivaptan also normalizes U(Na)V without affecting creatinine clearance and arterial pressure. [2] Conivaptan (0.01 to 0.1 mg/kg i.v.) exerts a dose-dependent diuretic effect in dogs without an increase in the urinary excretion of electrolytes, inhibits the pressor effect of exogenous vasopressin in a dose-dependent manner (0.003 to 0.1 mg/kg i.v.) and, at the highest dose (0.1 mg/kg i.v.), almost completely blocks vasoconstriction caused by exogenous vasopressin. Conivaptan (0.1 mg/kg i.v.) improves cardiac function, as evidenced by significant increases in left ventricular dP/dtmax, cardiac output and stroke volume, and reduces preload and afterload, as evidenced by significant decreases in left ventricular end-diastolic pressure and total peripheral vascular resistance in dogs with congestive heart failure. [3] |
Kinase Assay | In vitro HDAC assay:HDAC activity is analyzed by using an HDAC assay kit. This assay is based on the ability of DU-145 nuclear extract, which is rich in HDAC activity, to mediate the deacetylation of the biotinylated [3H]-acetyl histone H4 peptide that is bound to streptavidin agarose beads. The release of [3H]-acetate into the supernatant is measured to calculate the HDAC activity. Sodium butyrate (0.25-1 mM) is used as a positive control. |
Synonyms | Precedex, (+)-Medetomidine hydrochloride, (S)-Medetomidine hydrochloride, Dexmedetomidine HCl |
Molecular Weight | 236.74 |
Formula | C13H16N2·HCl |
CAS No. | 145108-58-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 23.7 mg/mL (100 mM)
H2O: 23.7 mg/mL (100 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Dexmedetomidine hydrochloride 145108-58-3 GPCR/G Protein Neuroscience Adrenergic Receptor Precedex inhibit Inhibitor adrenoceptor (+)-Medetomidine (+)-Medetomidine hydrochloride Dexmedetomidine analgesia (S)-Medetomidine hydrochloride sedation Beta Receptor anxiolysis (S)-Medetomidine Dexmedetomidine Hydrochloride Dexmedetomidine HCl Medetomidine Hydrochloride inhibitor